Nefopam Venipharm (Nefopam Hydrochloride)

Nefopam acts by inhibiting the reuptake of serotonin, norepinephrine and dopamine, and by blocking sodium channels. This combination enhances descending inhibitory pathways in the central nervous system and reduces neuronal excitability, resulting in analgesic effects without engaging opioid receptors.

The dosage of Nefopam Venipharm is determined by the prescribing clinician based on the patient’s condition, severity of pain, and route of administration. Healthcare professionals adjust the dose according to clinical guidelines and individual response.

Safety data for nefopam in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with opioid analgesics, nefopam provides effective pain relief without the risk of opioid‑related dependence or respiratory depression. Its multimodal mechanism differs from NSAIDs, offering an alternative for patients who cannot tolerate anti‑inflammatory drugs or who require opioid‑sparing strategies.

Nefopam Venipharm should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

The medication is supplied as an injectable solution and can be given either intramuscularly or intravenously. Administration is performed by qualified healthcare personnel, following aseptic technique and the dosage instructions provided by the prescriber.

Serious adverse events include seizures, severe hypotension, anaphylactic reactions, cardiac arrhythmias, and hepatic dysfunction. Patients with a history of seizures, cardiovascular disease, or known hypersensitivity should be closely monitored, and any signs of these reactions require immediate medical attention.

Nefopam Venipharm is contraindicated in patients with known hypersensitivity to nefopam or any excipients, those currently taking monoamine oxidase inhibitors, and individuals with uncontrolled epilepsy or severe cardiac conduction disorders. Clinicians should evaluate each patient’s medical history before prescribing.